Raised $12M across disclosed rounds.[1][2]

Seed closed May 2026, led by Accel.[1][2]

post-money valuation is not publicly disclosed.

Named investors include Accel, Air Street Capital, Elder Gull.[1]

Tilman Flock, Co-founder & CEO[1]

Martin Copes, Co-founder[1]

Zaki Trache, Co-founder[1]

Tilman Flock, CEO[1]

Isomorphic Labs · isomorphiclabs.com · Same buyer (big pharma R&D), same macro category (AI for drug discovery), but Isomorphic focuses on molecular-level point tools (structure prediction, molecule design) rather than cross-stage data integration—Perceptic explicitly positions against this...[1]

Recursion Pharmaceuticals · recursion.com · Same buyer segment and AI-for-drug-discovery category; Recursion is a point-tool competitor (wet-lab automation + ML) that Perceptic's CEO cited as an example of the siloed approach Perceptic is designed to bridge.[1]

Insilico Medicine · insilico.com · Named by CEO as representative of the point-tool cohort Perceptic differentiates from; same pharma R&D buyer but focused on specific discovery stages rather than cross-lifecycle data orchestration.[1]

Palantir Technologies (AIP for Life Sciences) · palantir.com · Closest workflow overlap: all three Perceptic founders built Palantir's AIP and its life sciences commercial practice. Perceptic is effectively a purpose-built, pharma-native alternative to Palantir AIP—same data-harmonization wedge, same pharma R&D buyer,...[1]

The customer proof is company-sourced only. No independent source in this ledger confirms it.[4]

Ask for one referenceable production customer.

Not a recommendation. The first thing this ledger cannot answer.

Filled in the side panel for invited readers. This card carries sourced facts only.